T-DXd Prevails in Trial of Second-Line Therapies for HER2 Gastroesophageal Cancer

By News Health
2 days Ago

(MedPage Today) — CHICAGO — Patients with progressive HER2-positive gastroesophageal (GE) cancer lived significantly longer when they received the antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) instead of ramucirumab…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115823

Author :

Publish date : 2025-05-31 12:00:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Pharmacists warn drug shortage affecting cancer patients

Tumor Treating Fields Boost Pancreatic Cancer Survival

Alternative Endpoints in Phase III Trials Don't Always Mean Boosts to OS, QOL

This Diet Pattern Is Linked With Worse Survival in Colon Cancer

Add-On Nivolumab Extends DFS in Locally Advanced Head and Neck Cancer

In Pancreatic Cancer, Does New PAXG Beat Out mFOLFIRINOX?